Evamist vs Veozah: Real-World Evidence Comparison for Menopause Hot Flashes

What Are These Two Drugs and How Do They Work?

Evamist and Veozah treat the same symptom, hot flashes, through mechanisms so different that comparing them is almost like comparing a thermostat replacement to a thermostat reset. Knowing which approach matches your biology matters more than picking the one with the better marketing.

Evamist: Estrogen Replacement Via Your Skin

Evamist is a metered-dose transdermal estradiol spray delivering 1.53 mg of estradiol-17β per spray to the inner forearm. One to three sprays daily provide systemic estrogen levels comparable to a low-to-mid-dose transdermal patch. The spray dries within 2 minutes, avoids the first-pass hepatic metabolism associated with oral estrogen, and produces steady serum estradiol concentrations.

Because Evamist is estrogen, it directly replenishes what your ovaries have stopped making. Vasomotor symptoms, vaginal dryness, sleep disruption, and mood changes linked to estrogen withdrawal can all respond. But estrogen alone is not the full picture for every woman.

Veozah: Resetting the Thermostat Without Hormones

Veozah (fezolinetant) belongs to an entirely new class. During menopause, falling estrogen causes hyperactivity in hypothalamic KNDy neurons that release neurokinin B (NKB). NKB binds NK3 receptors and triggers the vasodilation cascade you experience as a hot flash. Fezolinetant selectively blocks NK3 receptors, quieting that cascade without introducing exogenous hormones.

This matters enormously for women who cannot or will not take estrogen: survivors of estrogen-receptor-positive breast cancer, women with a personal or strong family history of VTE, or women who simply prefer a hormone-free path.

The Clinical Evidence: What Trials Actually Show

Both drugs have randomized, placebo-controlled trial data. Neither has been directly compared head-to-head in a published trial as of early 2025. The comparison below is indirect and you should treat the numbers accordingly.

Evamist Trial Data

The key Phase 3 RCT for Evamist enrolled 454 postmenopausal women with at least 7 moderate-to-severe hot flashes per day. At week 12, women using 1 or 2 sprays daily saw approximately 74% reductions in hot flash frequency from baseline, compared with roughly 51% in the placebo arm. Severity scores fell in parallel. The FDA approved Evamist in 2007 based on this and supporting pharmacokinetic data.

What the trial did not do: it did not enroll perimenopausal women with irregular cycles, did not report data by race or BMI subgroup in the main paper, and did not follow women longer than 12 weeks in the primary endpoint period.

SKYLIGHT-1 and SKYLIGHT-2: Fezolinetant's Evidence Base

The SKYLIGHT-1 trial (Lancet, 2023) randomized 501 postmenopausal women aged 40-65 to fezolinetant 30 mg, fezolinetant 45 mg, or placebo once daily for 12 weeks. The 45 mg dose (the approved dose) reduced mean weekly moderate-to-severe hot flash frequency by approximately 50% versus placebo at week 12, and reduced severity scores significantly. The 30 mg arm also outperformed placebo, but the 45 mg dose showed more consistent benefit. SKYLIGHT-2 replicated these findings in a second independent cohort.

A clinically useful framework: Evamist and Veozah appear to achieve roughly similar order-of-magnitude reductions in hot flash frequency (both in the 50-74% range from baseline in their respective trials), but the patient populations, trial designs, and comparator arms differ enough that these numbers are not interchangeable. Direct comparison awaits a head-to-head study.

Real-World Evidence: What We Know So Far

As of early 2025, published real-world evidence specifically for Evamist is limited to post-marketing pharmacovigilance data and small observational series. For fezolinetant, the FDA approved Veozah in May 2023, making strong real-world data sets still accumulating. Early post-marketing reports from specialty menopause practices suggest adherence rates for fezolinetant are high in the first 6 months among women who are already motivated to avoid hormones, though controlled adherence comparisons with transdermal estradiol have not been published.

The Menopause Society's 2023 position statement on nonhormone therapy identifies fezolinetant as a new category of centrally-acting agent with Level I evidence for vasomotor symptom reduction, placing it alongside but not above established hormone therapy options in terms of evidence quality.

How They Differ by Life Stage and Hormonal Status

Your reproductive stage shapes which drug makes more sense. This is where the two options really diverge.

Perimenopause (Still Having Periods, But Irregular)

Estradiol spray is an option during perimenopause, but it must be paired with progestogen if your uterus is intact, because unopposed estrogen increases endometrial hyperplasia risk. Veozah was studied in postmenopausal women (defined as 12 months of amenorrhea) in both SKYLIGHT trials, so its safety and efficacy in perimenopause with active cycles is not directly established by trial data. This is an honest evidence gap you should discuss with your clinician.

Early Postmenopause (Within 10 Years of Last Period, Under Age 60)

This is the Menopause Society's "timing hypothesis" window, where hormone therapy confers the most favorable cardiovascular risk profile. For women in this group without HRT contraindications, Evamist plus a progestogen (if uterus is present) is often a first-line choice. Veozah is appropriate for women in this group who decline hormones or have contraindications.

Late Postmenopause (Over Age 60, or More Than 10 Years Since Menopause)

Starting estrogen for the first time after this threshold carries higher cardiovascular and VTE risk according to ACOG Practice Bulletin 141. Veozah becomes a more attractive option here because it does not affect clotting factors, lipids, or the cardiovascular risk profile.

Women With Surgical Menopause

Women who had bilateral oophorectomy before natural menopause experience an abrupt, more severe estrogen deficit. Symptom burden is often higher. Estradiol spray can address that deficit directly and may be preferred, assuming no contraindications. Dose requirements may be higher than in natural menopause.

Sex-Specific Pharmacokinetics and Dosing

Evamist Dosing and Absorption in Women

The recommended starting dose is one spray (1.53 mg estradiol) applied to the inner forearm daily. Your clinician may increase to two or three sprays based on symptom response and serum estradiol levels. Absorption varies by skin thickness, which changes with age and body composition. Women with higher BMI may need closer monitoring because adipose tissue both stores and aromatizes estrogens, altering the effective circulating level.

Alcohol-containing skincare products applied to the spray site within one hour can substantially increase absorption. Body lotion applied before the spray is not the same risk as applying it after, but the safest practice is to avoid any topical product on the spray site for at least 60 minutes.

Veozah Dosing and Hepatic Metabolism

Fezolinetant 45 mg orally once daily is the only approved dose. It is metabolized by CYP1A2. Women who smoke (CYP1A2 inducers) may have lower fezolinetant exposure; women taking fluvoxamine or ciprofloxacin (CYP1A2 inhibitors) should not take fezolinetant because of significantly elevated drug levels and liver toxicity risk. The FDA prescribing information for Veozah lists CYP1A2 inhibitors as a contraindication.

Body weight does not appear to meaningfully alter fezolinetant exposure in the SKYLIGHT pharmacokinetic analyses.

Safety Profiles: Side Effects, Monitoring, and Risk

Evamist Safety

The safety profile of transdermal estradiol is well established over decades. Key risks relevant to women:

• VTE risk: Transdermal estradiol carries lower VTE risk than oral estradiol. A large French cohort study (Canonico et al.) found no significant increase in VTE with transdermal compared to oral formulations, though absolute risk is not zero.
• Breast cancer: Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk with extended use, per WHI data. Estrogen alone (in women without a uterus) showed no significant increase in the WHI estrogen-alone arm.
• Endometrial protection: Evamist requires concurrent progestogen in women with an intact uterus. This is not optional.
• Skin transfer: The spray can transfer to others via skin contact before it dries. Children and male partners are at risk of unintended estrogen exposure.

Veozah Safety

• Liver toxicity: The most clinically distinctive safety concern. The FDA mandates liver function testing at baseline, 3 months, and 6 months. In SKYLIGHT trials, transaminase elevations occurred in a small percentage of participants, most resolved with discontinuation.
• No cardiovascular signal: No increase in VTE, stroke, or cardiac events was seen in SKYLIGHT trials up to 52 weeks.
• Abdominal discomfort: The most commonly reported side effect in trials, typically mild and self-limiting.
• No endometrial effect: Because Veozah has no hormonal activity, endometrial monitoring is not required.

Pregnancy, Lactation, and Contraception

Both Evamist and Veozah are contraindicated during pregnancy and should not be used by women who are or may become pregnant.

Evamist in Pregnancy and Lactation

Evamist is FDA Pregnancy Category X. Exogenous estrogens carry risks of fetal genital abnormalities and are not indicated in pregnancy under any circumstances. Estradiol transfers into breast milk and may suppress lactation. Women who are breastfeeding should not use Evamist, and the drug is not appropriate for premenopausal women unless prescribed for a specific, non-menopausal indication under specialist supervision.

Women of perimenopausal age who still have any possibility of ovulation must use reliable contraception if using Evamist, because the drug does not prevent pregnancy and irregular cycles in perimenopause do not equal infertility.

Veozah in Pregnancy and Lactation

Fezolinetant has no human pregnancy data. Animal reproductive studies showed adverse fetal outcomes at exposures above the therapeutic range. Because of the mechanism of action (NK3 receptor antagonism affects hypothalamic-pituitary signaling), there is theoretical concern about interference with reproductive hormonal regulation. The FDA label states that Veozah should not be used in pregnancy, and advises pregnancy testing before initiation in women who could conceive.

No human data on lactation transfer exists. Given the unknowns, Veozah should not be used by breastfeeding women.

Women in perimenopause who still ovulate occasionally should use contraception while taking Veozah, not because the drug is contraceptive, but because it does not prevent conception and its fetal safety is unknown.

Who Is This Right For and Who Should Consider the Other Option

Evamist Is Likely the Better Fit If You:

• Are in early postmenopause (under 60, within 10 years of last period) with no HRT contraindications
• Have significant vaginal dryness or genitourinary syndrome of menopause (GSM) alongside hot flashes, because systemic estrogen addresses both
• Had surgical menopause and need estrogen replacement for bone protection as well as symptom relief
• Are comfortable with daily spray application and have no concerns about skin-to-skin transfer risk
• Have not responded adequately to lifestyle modifications or non-hormonal OTC options

You will need a progestogen added if your uterus is intact, and you will need annual gynecologic follow-up.

Veozah Is Likely the Better Fit If You:

• Are a breast cancer survivor (particularly ER-positive) for whom estrogen is contraindicated, per ACOG and ASCO guidance
• Have a personal history of VTE, DVT, or pulmonary embolism
• Are over 60 or more than 10 years past your last period, where initiating systemic estrogen carries higher cardiovascular risk
• Have a strong family history of breast cancer and prefer to avoid exogenous hormones
• Are in late perimenopause or postmenopause and want a hormone-free oral tablet without patch adhesion or spray logistics
• Have normal liver function and no CYP1A2 inhibitor use

You will need liver function tests at baseline, 3 months, and 6 months.

Neither May Be Right If You:

• Are trying to conceive (both are contraindicated in pregnancy)
• Have severe hepatic impairment (relevant primarily to Veozah)
• Are taking CYP1A2 inhibitors (Veozah contraindicated; drug interaction review needed for Evamist as well)
• Are currently pregnant or breastfeeding

Switching From Evamist to Veozah: A Practical Guide

Some women start on estradiol spray and later want to transition to a hormone-free option, perhaps after a new breast cancer diagnosis, after a VTE, or simply because they want to discontinue hormones after reaching a stable postmenopausal state.

What to Expect When Switching

There is no published protocol for tapering Evamist before starting Veozah. Based on pharmacokinetics, transdermal estradiol levels drop significantly within 3 to 5 days of stopping the spray. Fezolinetant reaches steady-state plasma levels within approximately 3 days of starting daily dosing.

In practice, many clinicians start Veozah on the same day they discontinue Evamist to minimize a symptom gap. A short overlap is not pharmacologically dangerous (Veozah has no estrogen activity), but it is also not tested in clinical trials. Discuss the exact timing with your prescriber.

Symptom Trajectory After Switching

Women stopping estrogen after extended use may experience a transient worsening of vasomotor symptoms as estrogen levels fall, even if Veozah is started simultaneously. Fezolinetant begins to show measurable benefit within 1 to 2 weeks in trial data, with near-maximal effect by week 4. Setting this expectation before switching reduces the chance of prematurely abandoning Veozah during the adjustment window.

Bone and Vaginal Health After Switching

Estrogen has bone-protective effects; Veozah does not. Women switching from long-term Evamist to Veozah should have a DXA scan if one has not been done recently, and should discuss supplemental calcium, vitamin D, and the possible need for a bone-specific agent (bisphosphonate or denosumab) with their clinician. Vaginal dryness and GSM will not be addressed by Veozah, so topical vaginal estrogen (which has minimal systemic absorption) may be continued alongside Veozah if needed.

Conditions Beyond Hot Flashes: Where Each Drug Has Reach

PCOS and Perimenopause

Women with PCOS entering perimenopause face a layered hormonal picture. Transdermal estradiol, because it avoids hepatic first-pass, does not worsen insulin resistance the way oral estrogens might, making Evamist a theoretically preferable estrogen route in this group. Fezolinetant's effect on LH pulse frequency in women with PCOS has not been studied, and no trial data exists for this population.

Osteoporosis Prevention

Estradiol spray, used consistently, has data supporting bone mineral density preservation. Veozah has no established bone benefit. For women whose primary reason for HRT is fracture risk reduction, Evamist (or another estrogen formulation) remains the evidence-backed choice.

Sleep and Mood

Both drugs may improve sleep secondarily by reducing night sweats. SKYLIGHT-1 reported significant improvements in sleep disturbance scores with fezolinetant 45 mg versus placebo at week 12. Estradiol's direct effects on sleep architecture and mood in menopausal women have been described in multiple observational studies, though trial-level evidence is less consistent.

Genitourinary Syndrome of Menopause (GSM)

Evamist, as systemic estrogen, improves vaginal atrophy, dryness, and dyspareunia alongside hot flashes. Veozah has no effect on GSM. Women with significant GSM who choose Veozah will need a separate topical estrogen or ospemifene for that indication.

Cost, Access, and Practical Considerations

Evamist is available as a brand-name product and through some compounding pharmacies as generic estradiol spray. It requires a prescription and, in women with a uterus, a concurrent progestogen prescription. Monthly cost with insurance varies widely; without insurance, branded Evamist can exceed $200 per month.

Veozah is brand-name only as of early 2025, with no generic available. List price is approximately $550 per month without insurance. The manufacturer (Astellas) offers a patient assistance program. Insurance coverage is variable and often requires prior authorization documenting contraindications to or failure of other therapies.

Both drugs require a telehealth or in-person consultation to prescribe. Neither is available over the counter.